Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events included hypertension and anemia. Evidence ...

A phase II trial shows that pembrolizumab and bevacizumab yield a 54.1% intracranial response rate and a median overall ...

Immune-Onc Therapeutics has dosed the first subject in the Phase Ib/II trial of IO-108 plus Roche’s atezolizumab and bevacizumab as a potential first-line treatment for hepatocellular carcinoma (HCC).

Researchers identify a history of GI bleeding and three other factors as elevating variceal bleeding risk in patients ...

One of the world's most globally recognised liver cancer treatments will receive public funding from today. Tecentriq (atezolizumab) in combination with bevacizumab will help the 70 or so New ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...

Intas Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Outlook Therapeutics (OTLK) announced it has re-submitted its Biologics License Application, BLA, to the U.S. Food and Drug Administration, ...

Drayson started taking cancer drugs atezolizumab with bevacizumab in December 2023 after being accepted for a clinical trial.

By Simeon Brown, Member of Parliament for Pakuranga There’s been some good news from Pharmac this month. The agency has ...